mTOR Inhibition in Lymphoma: A Rational and Promising Strategy

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|4|3|224-231

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.4, Iss.3, 2007-04, pp. : 224-231

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Applicability of mTOR Inhibition in Solid Tumors

By  

Current Cancer Drug Targets, Vol. 9, Iss. 3, 2009-05 ,pp. : 439-450

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

By O'Regan Ruth   Hawk Natalyn Nicole  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 7, 2011-07 ,pp. : 859-872

Informa Healthcare

Access to resources Recommend Favorite

mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma

By  

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 945-954

Bentham Science Publishers

Access to resources Recommend Favorite

Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials

By Naing Aung  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 679-685

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

By  

Current Clinical Pharmacology, Vol. 6, Iss. 3, 2011-08 ,pp. : 214-221

Bentham Science Publishers

Access to resources Recommend Favorite